CN108368100B - 一种泰地唑胺的制备方法及其中间体和制备方法 - Google Patents
一种泰地唑胺的制备方法及其中间体和制备方法 Download PDFInfo
- Publication number
- CN108368100B CN108368100B CN201680054697.8A CN201680054697A CN108368100B CN 108368100 B CN108368100 B CN 108368100B CN 201680054697 A CN201680054697 A CN 201680054697A CN 108368100 B CN108368100 B CN 108368100B
- Authority
- CN
- China
- Prior art keywords
- group
- palladium
- halogen
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/02—Sulfur, selenium or tellurium; Compounds thereof
- B01J27/053—Sulfates
- B01J27/055—Sulfates with alkali metals, copper, gold or silver
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/06—Halogens; Compounds thereof
- B01J27/08—Halides
- B01J27/122—Halides of copper
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0201—Oxygen-containing compounds
- B01J31/0211—Oxygen-containing compounds with a metal-oxygen link
- B01J31/0212—Alkoxylates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0235—Nitrogen containing compounds
- B01J31/0237—Amines
- B01J31/0238—Amines with a primary amino group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2282—Unsaturated compounds used as ligands
- B01J31/2295—Cyclic compounds, e.g. cyclopentadienyls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
- B01J31/28—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
- B01J31/28—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper
- B01J31/30—Halides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/40—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the same carbon atom of the carbon skeleton, e.g. amino-ketals, ortho esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
- B01J2231/44—Allylic alkylation, amination, alkoxylation or analogues
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium
Abstract
本发明涉及下式泰地唑胺化合物的制备方法,式I,其中,R选自氢、式A、式B、苄基或取代基取代的苄基,所述取代基选自卤素、硝基、C1‑C6烷基和C1‑C6烷氧基组成的组,R1为C1‑C6烷基或卤素取代的C1‑C6烷基;包括将具有下式结构的化合物式C与具有下式结构的化合物式D,在金属催化剂催化下偶联反应生成,R的取代基定义同上;其中X为离去基团,所述离去基团包括氯、溴、碘,磺酰氧基如三氟甲磺氧基、甲磺酰氧基、苯磺酰氧基,或被一个或多个取代基取代的苯磺酰氧基,所述取代基选自卤素、C1‑C6烷基和C1‑C6烷氧基组成的组。
Description
本申请要求于2015年11月3日提交中国专利局、申请号为201510739910.6发明名称为“一种泰地唑胺的制备方法及其中间体”的中国专利申请的优先权,其全部内容通过引用结合在本申请中。
技术领域
本发明涉及一种新噁唑烷酮类抗菌素泰地唑胺或其磷酸盐的制备方法及其中间体化合物和制备方法。
背景技术
磷酸泰地唑胺,对包括革兰氏阳性菌如葡萄球菌、肠道球菌和链球菌,厌氧微生物如类菌体和梭菌体以及耐酸微生物如结核分支菌、鸟分支菌在内的人和动物病原体具有有力的抗菌活性。由Cubist Pharmaceuticals公司(Merck公司的子公司)和拜耳共同开发了tedizolid(以前称为torezolid),最初由Dong-A Pharmaceutical东亚制药(东亚ST)发现了抗菌药物前体,用于对革兰氏阳性菌感染的治疗,Tedizolid在血浆中迅速转化成其活性形式,TR 700(DA 7157)。
WO2005058886A1公开了3-[3-氟-4-[6-(2-甲基-2H-四唑-5-基)-3-吡啶基]苯基]-5-(羟基甲基)-2-噁唑烷酮的合成,使用3-氟苯胺为原料,经过Cbz保护,再与缩水甘油丁酸酯反应得到化合物3,碘代后再制备成锡试剂5,之后与5-溴-2-(2-甲基-2H-四唑-5-基)-吡啶suzuki偶联得到关键中间体K,反应路线如下:
该东亚制药原研的化合物的反应步骤较长,总收率不高。成本方面,需要使用比较昂贵的试剂如CF3COOAg,而且路线中两次使用Pd催化剂分别用于制备中间体5和K,条件苛刻不易于放大生产。
后来原研许可商Trius Therapeutics公司对原研化合物路线进行了改进,其专利WO2010042887采用以4-溴-3-氟苯胺为起始原料,合成硼酸酯10,再与5-溴-2-(2-甲基-2H-四唑-5-基)-吡啶进行suzuki偶联生成中间体11,然后再与缩水甘油丁酸酯反应生成噁唑烷酮中间体K,反应路线如下:
相对东亚制药的专利方法,该路线步骤短,总收率有所提高,但反应条件比较苛刻,需要使用丁基锂并在超低温(-65℃)下进行;并且n-BuLi和LiHMDS的使用需要严格的无水条件。
另外CN104496979A公开了一种制备泰地唑胺的方法,反应路线如下:
其中,R为氢或羟基保护基;L和R1中一个为离去基团,另一个为BF3或BR2R3,其中R2和R3独立的选自由OH和任意取代的C1-C6一元和二元醇组成的组,其中R2和R3可以成环;该路线采用Pd催化合成硼酸酯中间体II,分离纯化出硼酸酯II后,再与化合物I在Pd催化条件下进行suzuki偶联得到式H所示化合物。路线中须分离出II,再进行suzuki偶联,操作繁琐。
目前关于泰地唑胺中间体的现有方法,均操作复杂,反应时间长,总收率低,纯度较低。
发明内容
本发明目的是提供一种生产成本低,操作简单,收率和纯度较高,适合工业化生产的泰地唑胺制备方法,具体涉及利用新颖中间体用于制备泰地唑胺的新型方法。
为实现上述目的,本发明提供了一种下式泰地唑胺化合物的制备方法,
包括将具有下式结构的化合物,
其中X为离去基团(所述离去基团包括氯、溴、碘,磺酰氧基如三氟甲磺氧基、甲磺酰氧基、苯磺酰氧基,或被一个或多个取代基取代的苯磺酰氧基,所述取代基选白卤素、C1-C6烷基和C1-C6烷氧基组成的组;优选离去基团为氯、溴或碘;更优选离去基团为溴或碘),
与具有下式结构的化合物,
在金属催化剂催化下偶联反应生成,其中R的取代基定义同上。
在本发明的优选实施方式中,金属催化剂为铜催化剂。所述同催化剂优选Cu粉、CuI、CuBr、Cu2O、CuO、Cu2O、CuSO4、Cu(OAc)2或Cu(OTf)2,更优选CuI和Cu(OAc)2。
除了单独使用铜催化剂,在某些情况下,也需要在配体的配合下进行反应,可以使用二胺类配体、二酮类配体、邻菲罗啉类配体、氨基酸类配体或Phos类配体。二胺类配体优选为:
二酮类配体优选为:
邻菲罗啉类配体优选为:
氨基酸类配体优选为:
Phos类配体优选为:X-Phos、XantPhos、RuPhos、BrettPhos、SPhos、DavePhos、JohnPhos、tBuXPhos。
在本发明的另一些实施方式中,金属催化剂为钯催化剂,比如氯化钯、醋酸钯、三(二亚苄基丙酮)二钯、双(二亚苄基丙酮)钯、四(三苯基膦)钯、[1,1’-双(二苯基磷)二茂铁]二氯化钯、双(三环己基膦)二氯化钯或双(三苯基膦)二氯化钯,优选三(二亚苄基丙酮)二钯、氯化钯或醋酸钯。
通常地,在碱性环境下(如醋酸钾、碳酸钠、碳酸钾、碳酸铯、氟化铯、氢氧化钠、氢氧化钾、磷酸钾或磷酸钠等)能够促进反应的进行。溶剂可以选白芳香烃、醚类、醇类、醚类、腈类及酰胺类等溶剂,优选为甲苯、氯苯、四氢呋喃(THF)、N,N-二甲基甲酰胺(DMF)、二甲基亚砜(DMSO)、二氧六环、异丙醇、乙醇或乙腈;进一步优选N,N-二甲基甲酰胺(DMF)和二氧六环。反应温度优选为60-110℃,更优选90-110℃。
上式所示化合物可以进一步磷酸化,得到如下式所示的磷酸泰地唑胺,
本发明还提供了新的泰地唑胺中间体,即下式化合物的制备方法,
其中X为离去基团,定义同上;
包括将具有下式结构的化合物
其中,C为羟基或氨基;
1)当C为羟基时,与磺酰氯类化合物(包括三氟甲酸酸酐、甲磺酰氯、或苯磺酰氯等)反应即可生成具有下式结构的化合物:
其中X为离去基团(所述离去基团为磺酰氧基如三氟甲磺氧基、甲磺酰氧基、苯磺酰氧基,或被一个或多个取代基取代的苯磺酰氧基,所述取代基选白卤素、C1-C6烷基和C1-C6烷氧基组成的组);
在这种情况下,加入碱性物质可促进反应的进行,如碳酸钾、碳酸钠、碳酸铯、氟化铯、醋酸钾、氢氧化钠、氢氧化钾、磷酸钾或磷酸钠等;
2)当C为氨基时,在亚硝酸钠存在下反应生成重氮盐化合物,再经卤素离子取代形成具有下式结构的化合物:
其中X为离去基团,所述离去基团包括氯、溴、碘;
在这种情况下,在酸性环境下如醋酸、甲磺酸、盐酸、硫酸、或樟脑磺酸的存在下,与亚硝酸钠反应形成重氮盐,形成的重氮盐被卤素离子取代形成上式所示化合物。卤素离子的供体可以是氯、溴或碘,以碘为例可以包括碘单质或碘盐例如碘化钠、或碘化钾等。
本发明还提供了一种新的泰地唑胺中间体,即下式化合物的制备方法,
包括将具有下式结构的化合物
与具有下式结构的化合物
在钯催化剂催化下偶联反应生成,
其中,C为羟基或氨基;A和B中一个为离去基团,另一个为BF3或BR2R3,其中R2和R3独立的选自由OH和C1-C6一元和二元醇或卤素取代的C1-C6一元和二元醇组成的组,R2和R3可以成环。
在一个实施方式中,优选A为离去基团,B为BF3或BR2R3,其中R2和R3独立的选自由OH和C1-C6一元和二元醇或卤素取代的C1-C6一元和二元醇组成的组,R2和R3可以成环。
在另一个实施方式中,优选B为离去基团,A为BF3或BR2R3,其中R2和R3独立的选自由OH和C1-C6一元和二元醇或卤素取代的C1-C6一元和二元醇组成的组,R2和R3可以成环。
其中,所述离去基团包括卤素如氯、溴、碘,磺酰氧基如三氟甲磺酰氧基、甲磺酰氧基、苯磺酰氧基,或被一个或多个取代基取代的苯磺酰氧基,所述取代基选白卤素、C1-C6烷基和C1-C6烷氧基组成的组;优选离去基团为氯、溴、碘;更优选离去基团为溴或碘。
在具体实施方式中,反应催化剂为钯催化剂,所述钯催化剂为氯化钯、醋酸钯、双(二亚苄基丙酮)钯、四(三苯基膦)钯、[1,1’-双(二苯基磷)二茂铁]二氯化钯、双(三环己基膦)二氯化钯或双(三苯基膦)二氯化钯等。
在碱性物质存在条件下可以促进反应的进行,如碳酸钾、碳酸钠、碳酸铯、氟化铯、醋酸钾、氢氧化钠、氢氧化钾、磷酸钾或磷酸钠。溶剂可以是水、甲苯、四氢呋喃(THF)、N,N-二甲基甲酰胺(DMF)、二甲基亚砜(DMSO)、二氧六环、异丙醇、乙醇或乙腈等一种或多种组合,优选为甲苯、水和二氧六环、或异丙醇。反应温度优选为50-120℃,更优选为70-100℃。
本发明还提供了新的泰地唑胺中间体,即结构式如下的化合物:
或结构式如下的化合物:
其中X为离去基团(所述离去基团包括氯、溴、碘,磺酰氧基如三氟甲磺氧基、甲磺酰氧基、苯磺酰氧基,或被一个或多个取代基取代的苯磺酰氧基,所述取代基选白卤素、C1-C6烷基和C1-C6烷氧基组成的组);所述离去基团优选溴或碘。所述化合物优选为:
本发明有益的技术效果:
相比于现有技术,本发明提供了一种新型的泰地唑胺制备方法,具有原料易得、成本低、各步收率高、工艺简洁易操作和环保经济等优点,利于工业化生产。其中,本发明专利涉及的制备方法需要使用到关键中间体5-(4-取代-2-氟苯基)-2-(2-甲基-2H-四唑-5-基)吡啶,该中间体的使用使得泰地唑胺的制备路线得以实施。
具体实施方式
实施例
为了使本发明所解决的技术问题、技术方案及有益效果更佳清楚明白,以下结合具体实施例,对本发明作进一步的说明。所给出的具体实施例为本发明的优选实施例。
实验和数据分析
试剂通过商业来源购买,未经处理直接使用。氢质子核磁共振谱通过BrukerAVANCE 400在400MHz下获得。质谱使用Agilent HPLC 1260 Infinity及6120 DuadrupoleLC/MS记录。
实施例1:2-(2-甲基-2H-四唑-5-基)-5-(4,4,5,5-四甲基-1,3,2-二氧代硼戊环-2-基)吡啶的制备
在装有搅拌和温度计的三口烧瓶中加入5-溴-2-(2-甲基-2H-四唑-5-基)吡啶(20.0g,1eq),频那醇硼酸酯(42.3g,2.0eq),醋酸钾(24.5g,3.0eq)及甲苯(400mL),N2置换后,加入Pd(dppf)Cl2(0.6g,3%w/w),再次N2置换后,于80-85℃下搅拌反应12小时,HPLC监控显示反应完全。反应液冷却至40-50℃,在此温度下抽滤,滤液加入5g活性炭,加热至70-80℃搅拌脱色1-2小时,冷却至40-50℃,在此温度下抽滤,滤液减压蒸馏至40-60mL,冷却至10-15℃,白色固体析出,过滤,滤饼放置于50℃下烘干,得到白色固体产品19.5g,收率81.5%。HPLC显示纯度为98.5%。LCMS[M+H]=288.1,NMR(CDCl3,400MHz):9.15(t,1H),8.22(m,2H),4.44(s,3H),1.25(s,12H)。
实施例2:3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯胺的制备
在装有搅拌和温度计的三口烧瓶中加入2-(2-甲基-2H-四唑-5-基)-5-(4,4,5,5-四甲基-1,3,2-二氧代硼戊环-2-基)吡啶(50g,1eq),4-溴-3-氟苯胺(36.4g,1.1eq),Na2CO3(36.9g,2.0eq),水(300mL)及二氧六环(1000mL),N2置换后,加入Pd(dppf)Cl2(1.5g,3%w/w),再次N2置换后,于70-80℃下搅拌反应12小时,HPLC监控显示反应完全。减压蒸馏去除大部分二氧六环,加入500mL水,室温搅拌2-3小时后,过滤,滤饼用乙醇(100mL)打浆,过滤,滤饼放置于50℃下烘干,得到灰白色固体产品42.3g,收率90%。HPLC显示纯度99.1%。LCMS[M+H]=271.0,NMR(DMSO-d6,400MHz):9.01(t,1H),8.54(s,2H),8.18(m,2H),7.75(t,1H),7.59(d,1H),7.29(d,1H),4.41(s,3H)。
实施例3:5-(2-氟-4-碘苯基)-2-(2-甲基-2H-四唑-5-基)吡啶的制备
在装有搅拌和温度计的三口烧瓶中加入3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯胺(30.0g,1eq)及醋酸(600mL)。室温搅拌溶解后,依次加入樟脑磺酸(30.9g,1.2eq),碘化钾(36.9g,2.0eq)及亚硝酸钠(9.2g,1.2eq),加完之后于室温下搅拌16小时。HPLC监控显示反应完全。减压蒸馏蒸出大部分醋酸,加入300mL水及500mL二氯甲烷,搅拌后分液,二氯甲烷层水洗后,减压蒸馏去除溶剂,得到棕黄色固体产品20.8g,收率49%。HPLC显示纯度96.7%。LCMS[M+H]=381.9,NMR(DMSO-d6,400MHz):8.85(s,1H),8.28(d,1H),8.01(d,1H),7.65(t,1H),7.56(dd,1H),7.19(d,1H),4.42(s,3H)。
实施例4:(R)-3-(3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯基)-5-(羟甲基)噁唑烷-2-酮的制备
在装有搅拌和温度计的三口烧瓶中加入5-(2-氟-4-碘苯基)-2-(2-甲基-2H-四唑-5-基)吡啶(50.0g,1eq),(R)-5-(羟甲基)噁唑烷-2-酮(23.0g,1.5eq),环己二胺(1.5g,0.1eq),碘化亚铜(1.3g,0.05eq),碳酸钾(36.3g,2.0eq)及二氧六环(500mL),N2置换后,于100-110℃下搅拌反应16小时,HPLC显示反应完全。减压蒸馏除去大部分溶剂,残留物加入1000mL水,加热回流1-2小时,冷却至70℃,抽滤,滤饼用DMF(150mL)打浆2小时,过滤,滤饼用水(300mL)重打浆,过滤,滤饼放置于65℃下烘干,得到灰白色固体产品38.5g,收率79.2%。HPLC显示纯度97.9%。LCMS[M+H]=371.1,NMR(DMSO-d6,400MHz):8.95(s,1H),8.24(d,1H),8.10(d,1H),7.78(t,1H),7.45(dd,1H),7.10(d,1H),4.62(m,1H),4.42(s,3H),3.84(m,1H),3.42-3.35(m,2H),3.01(m,1H)。
实施例5:3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯酚的制备
在装有搅拌和温度计的三口烧瓶中加入2-(2-甲基-2H-四唑-5-基)-5-(4,4,5,5-四甲基-1,3,2-二氧代硼戊环-2-基)吡啶(25g,1eq),4-溴-3-氟苯酚(19.9g,1.2eq),Na2CO3(18.5g,2.0eq),水(120mL)及二氧六环(600mL),N2置换后,加入Pd(dppf)Cl2(0.75g,3%w/w),再次N2置换后,于70-80℃下搅拌反应12小时,HPLC监控显示反应完全。减压蒸馏去除大部分二氧六环,加入500mL水,室温搅拌2-3小时后,过滤,滤饼用异丙醇醇(70mL)打浆,过滤,滤饼放置于50℃下烘干,得到白色固体产品18.2g,收率77%。HPLC显示纯度99.5%。LCMS[M+H]=272.0,NMR(DMSO-d6,400MHz):10.20(s,1H),9.11(s,1H),8.54(d,1H),8.18(d,1H),7.75(t,1H),7.59(d,1H),7.29(d,1H),4.39(s,3H)。
实施例6:3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯基三氟甲烷磺酸酯的制备
在装有搅拌和温度计的三口烧瓶中加入3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯酚(15g,1eq),三氟甲烷磺酸酐(23.4g,1.5eq),吡啶(6.6g,1.5eq),及四氢呋喃(150mL),N2置换后,加热回流搅拌反应5小时,HPLC监控显示反应完全。减压蒸馏去除大部分四氢呋喃,加入100mL乙酸乙酯及100mL水,室温搅拌后,分液,有机相干燥后,蒸馏去除溶剂,得到白色固体产品20.0g,收率90%。HPLC显示纯度96.3%。LCMS[M+H]=403.9,NMR(DMSO-d6,400MHz):9.12(s,1H),8.44(d,1H),8.08(d,1H),7.85(t,1H),7.67(d,1H),7.28(d,1H),4.33(s,3H)。
实施例7:(R)-3-(3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯基)-5-(羟甲基)噁唑烷-2-酮的制备
在装有搅拌和温度计的三口烧瓶中加入3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯基三氟甲烷磺酸酯(10.0g,1eq),(R)-5-(羟甲基)噁唑烷-2-酮(3.8g,1.3eq),Pd(dppf)Cl2(300mg,3%w/w),XantPhos(300mg,3%w/w),碳酸钾(6.9g,2.0eq)及二氧六环(80mL),N2置换后,于100-110℃下搅拌反应16小时,HPLC显示反应完全。减压蒸馏除去大部分溶剂,残留物加入100mL水,加热回流1-2小时,冷却至70℃,抽滤,滤饼用DMF(50mL)打浆2小时,过滤,滤饼用水(150mL)重打浆,过滤,滤饼放置于65℃下烘干,得到灰白色固体产品6.1g,收率66%。HPLC显示纯度96.9%。LCMS[M+H]=371.1,NMR(DMSO-d6,400MHz):8.95(s,1H),8.24(d,1H),8.10(d,1H),7.78(t,1H),7.45(dd,1H),7.10(d,1H),4.62(m,1H),4.42(s,3H),3.84(m,1H),3.42-3.35(m,2H),3.01(m,1H)。
实施例8:磷酸泰地唑胺的制备
在装有搅拌和温度计的三口烧瓶中加入(R)-3-(3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯基)-5-(羟甲基)噁唑烷-2-酮(10.0g,1eq)及四氢呋喃(200mL),N2置换后,冷却至0℃,滴加三乙胺(8.2g,3eq)。搅拌下控温0-10℃滴加三氯氧磷(12.4g,3eq),滴加完毕反应慢慢升至室温,反应20小时,HPLC显示反应完全。将反应液慢慢滴入100mL冰水中,搅拌过夜,过滤,50mL水洗后,得滤饼。滤饼于65℃下烘20小时得到白色固体粗品,粗品用40mL甲醇打浆,过滤,滤饼放置于65℃下烘干,得到白色固体纯品6.8g,收率56%。HPLC显示纯度99.7%。LCMS[M+H]=451.1,NMR(DMSO-d6,400MHz):8.95(s,1H),8.24(d,1H),8.10(d,1H),7.78(t,1H),7.45(dd,1H),7.10(d,1H),4.62(m,1H),4.42(s,3H),3.84(m,1H),3.42-3.35(m,2H),3.01(m,1H)。
实施例9:3-氟-4-(4,4,5,5-四甲基-1,3,2-二氧代硼戊环-2-基)苯胺的制备
在装有搅拌和温度计的三口烧瓶中加入4-溴-3-氟苯胺(50.0g,1eq),频那醇硼酸酯(100.2g,1.5eq),醋酸钾(77.5g,3.0eq)及甲苯(500mL),N2置换后,加入Pd(dppf)Cl2(1.5g,3%w/w),再次N2置换后,于80-85℃下搅拌反应8小时,HPLC监控显示反应完全。反应液冷却至40-50℃,在此温度下抽滤,滤液加入10g活性炭,加热至70-80℃搅拌脱色1-2小时,冷却至40-50℃,在此温度下抽滤,滤液减压蒸馏至80-100mL,冷却至10-15℃,白色固体析出,过滤,滤饼放置于50℃下烘干,得到白色固体产品54g,收率87%。HPLC显示纯度为98.9%。LCMS[M+H]=238.1,NMR(DMSO-d6,400MHz):7.51(d,1H),7.02(s,1H),6.87(d,1H),6.51(s,2H),1.25(s,12H)。
实施例10:3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯胺的制备
在装有搅拌和温度计的三口烧瓶中加入3-氟-4-(4,4,5,5-四甲基-1,3,2-二氧代硼戊环-2-基)苯胺(15g,1eq),5-溴-2-(2-甲基-2H-四唑-5-基)吡啶(18.2g,1.2eq),Na2CO3(13.4g,2.0eq),水(60mL)及二氧六环(300mL),N2置换后,加入Pd(dppf)Cl2(450mg,3%w/w),再次N2置换后,于70-80℃下搅拌反应12小时,HPLC监控显示反应完全。减压蒸馏去除大部分二氧六环,加入150mL水,室温搅拌2-3小时后,过滤,滤饼用乙醇(80mL)打浆,过滤,滤饼放置于50℃下烘干,得到灰白色固体产品14.8g,收率87%。HPLC显示纯度98.3%。LCMS[M+H]=271.0,NMR(DMSO-d6,400MHz):9.01(t,1H),8.54(s,2H),8.18(m,2H),7.75(t,1H),7.59(d,1H),7.29(d,1H),4.41(s,3H)。
实施例11:3-氟-4-(4,4,5,5-四甲基-1,3,2-二氧代硼戊环-2-基)苯酚的制备
在装有搅拌和温度计的三口烧瓶中加入4-溴-3-氟苯酚(30.0g,1eq),频那醇硼酸酯(59.8g,1.5eq),醋酸钾(46.3g,3.0eq)及甲苯(300mL),N2置换后,加入Pd(dppf)Cl2(0.9g,3%w/w),再次N2置换后,于80-85℃下搅拌反应8小时,HPLC监控显示反应完全。反应液冷却至40-50℃,在此温度下抽滤,滤液加入10g活性炭,加热至70-80℃搅拌脱色1-2小时,冷却至40-50℃,在此温度下抽滤,滤液减压蒸馏至60-80mL,冷却至0-10℃,白色固体析出,过滤,滤饼放置于50℃下烘干,得到白色固体产品29.8g,收率80%。HPLC显示纯度为99.5%。LCMS[M+H]=239.0,NMR(DMSO-d6,400MHz):10.50(s,1H),7.65(d,1H),7.42(s,1H),7.01(d,1H),1.26(s,12H)。
实施例12:3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯酚的制备
在装有搅拌和温度计的三口烧瓶中加入3-氟-4-(4,4,5,5-四甲基-1,3,2-二氧代硼戊环-2-基)苯酚(18.0g,1eq),5-溴-2-(2-甲基-2H-四唑-5-基)吡啶(21.8g,1.2eq),Na2CO3(16.0g,2.0eq),水(54mL)及二氧六环(270mL),N2置换后,加入Pd(dppf)Cl2(540mg,3%w/w),再次N2置换后,于70-80℃下搅拌反应12小时,HPLC监控显示反应完全。减压蒸馏去除大部分二氧六环,加入300mL水,室温搅拌2-3小时后,过滤,滤饼用异丙醇醇(90mL)打浆,过滤,滤饼放置于50℃下烘干,得到白色固体产品16.0g,收率78%。HPLC显示纯度98.9%。LCMS[M+H]=272.0,NMR(DMSO-d6,400MHz):10.20(s,1H),9.11(s,1H),8.54(d,1H),8.18(d,1H),7.75(t,1H),7.59(d,1H),7.29(d,1H),4.39(s,3H)。
实施例13:(R)-2-((苄氧基)甲基)环氧乙烷的制备
在装有搅拌和温度计的三口烧瓶中加入苄醇(50g,1eq),氢氧化钾水溶液300mL(50%w/w),TBAB(14.9g,0.1eq)及二氯甲烷(300mL),冷却至0-10℃,缓慢滴加环氧氯丙烷(64.2g,1.5eq),滴加完毕,升至室温反应16小时,HPLC监控显示反应完全。停止搅拌,分液,水相用二氯甲烷300mL萃取一次,合并有机相,未经提纯直接用于下一步反应。
实施例14:(R)-1-氨基-3-(苄氧基)异丙醇的制备
在装有搅拌的氢化瓶中加入(R)-2-((苄氧基)甲基)环氧乙烷的二氯甲烷溶液及100mL氨水,密封后,加热至35℃,搅拌反应16小时,HPLC监控显示反应完全。停止搅拌,加入300mL水,搅拌后分液,有机相用0.1M的HCl溶液(100mL)洗涤,分去二氯甲烷,水相用NaOH调pH=9-10,二氯甲烷萃取(300mL),浓缩二氯甲烷得到无色液体产品55.0g,两步收率66%。HPLC显示纯度98.4%。LCMS[M+H]=182.0,NMR(DMSO-d6,400MHz):7.42-7.25(m,5H),5.11(s,2H),4.54(s,2H),3.68(m,1H),3.50-3.34(m,2H),3.12-3.06(br,1H),3.00-2.89(m,2H)。
实施例15:(R)-5-((苄氧基)甲基)噁唑烷-2-酮的制备
在装有搅拌的三口瓶中加入(R)-1-氨基-3-(苄氧基)异丙醇(20g,1eq)及四氢呋喃(200mL),加热至35℃,加入CDI(26.8g,1.5eq),保温搅拌反应16小时,HPLC监控显示反应完全。停止搅拌,浓缩四氢呋喃溶液后,加入乙酸乙酯200mL及1M盐酸100mL,搅拌后分液,有机相用水洗涤后,浓缩乙酸乙酯得到无色液体产品21.0g,收率92%。HPLC显示纯度99.0%。LCMS[M+H]=208.0,NMR(DMSO-d6,400MHz):8.05(s,1H),7.44-7.22(m,5H),4.56(s,2H),4.28-4.20(m,1H),3.77-3.69(m,1H),3.42-3.29(m,2H),3.11-3.06(m,1H)。
实施例16:(R)-5-(羟甲基)噁唑烷-2-酮的制备
在装有搅拌的三口瓶中加入(R)-5-((苄氧基)甲基)噁唑烷-2-酮(15g,1eq),四氢呋喃(150mL)及Pd/C(1.5g,10%w/w),氢气置换后,加热至45℃,保温搅拌反应3小时,HPLC监控显示反应完全。停止搅拌,过滤去除Pd/C后,浓缩四氢呋喃得到无色油状产品8.4g,收率99%。HPLC显示纯度98.6%。LCMS[M+H]=117.9,NMR(DMSO-d6,400MHz):7.92(s,1H),4.68-4.60(m,1H),3.97-3.90(m,1H),3.70(br,1H),3.62-3.55(m,2H),3.11-3.06(m,1H)。
实施例17:(R)-3-(3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯基)-5-(羟甲基)噁唑烷-2-酮的制备
在装有搅拌和温度计的三口烧瓶中加入5-(2-氟-4-碘苯基)-2-(2-甲基-2H-四唑-5-基)吡啶(50.0g,1eq),(R)-5-(羟甲基)噁唑烷-2-酮(23.0g,1.5eq),环己二胺(1.5g,0.1eq),硫酸铜(1.05g,0.05eq),碳酸钾(36.3g,2.0eq)及二氧六环(500mL),N2置换后,于100-110℃下搅拌反应16小时,HPLC显示反应完全。减压蒸馏除去大部分溶剂,残留物加入1000mL水,加热回流1-2小时,冷却至70℃,抽滤,滤饼用DMF(150mL)打浆2小时,过滤,滤饼用水(300mL)重打浆,过滤,滤饼放置于65℃下烘干,得到灰白色固体产品36.3g,收率74.7%。HPLC显示纯度98.3%。LCMS[M+H]=371.1,NMR(DMSO-d6,400MHz):8.95(s,1H),8.24(d,1H),8.10(d,1H),7.78(t,1H),7.45(dd,1H),7.10(d,1H),4.62(m,1H),4.42(s,3H),3.84(m,1H),3.42-3.35(m,2H),3.01(m,1H)。
实施例18:(R)-3-(3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯基)-5-(羟甲基)噁唑烷-2-酮的制备
在装有搅拌和温度计的三口烧瓶中加入5-(2-氟-4-碘苯基)-2-(2-甲基-2H-四唑-5-基)吡啶(50.0g,1eq),(R)-5-(羟甲基)噁唑烷-2-酮(23.0g,1.5eq),环己二胺(1.5g,0.1eq),Cu(OAc)2(1.19g,0.05eq),碳酸钾(36.3g,2.0eq)及二氧六环(500mL),N2置换后,于100-110℃下搅拌反应16小时,HPLC显示反应完全。减压蒸馏除去大部分溶剂,残留物加入1000mL水,加热回流1-2小时,冷却至70℃,抽滤,滤饼用DMF(150mL)打浆2小时,过滤,滤饼用水(300mL)重打浆,过滤,滤饼放置于65℃下烘干,得到灰白色固体产品39.9g,收率82.1%。HPLC显示纯度97.8%。LCMS[M+H]=371.1,NMR(DMSO-d6,400MHz):8.95(s,1H),8.24(d,1H),8.10(d,1H),7.78(t,1H),7.45(dd,1H),7.10(d,1H),4.62(m,1H),4.42(s,3H),3.84(m,1H),3.42-3.35(m,2H),3.01(m,1H)。
实施例19:(R)-3-(3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯基)-5-(羟甲基)噁唑烷-2-酮的制备
在装有搅拌和温度计的三口烧瓶中加入5-(2-氟-4-碘苯基)-2-(2-甲基-2H-四唑-5-基)吡啶(50.0g,1eq),(R)-5-(羟甲基)噁唑烷-2-酮(23.0g,1.5eq),环己二胺(1.5g,0.1eq),三(二亚苄基丙酮)二钯(1.5g,3%w/w),碳酸钾(36.3g,2.0eq)及二氧六环(500mL),N2置换后,于100-110℃下搅拌反应16小时,HPLC显示反应完全。减压蒸馏除去大部分溶剂,残留物加入1000mL水,加热回流1-2小时,冷却至70℃,抽滤,滤饼用DMF(150mL)打浆2小时,过滤,滤饼用水(300mL)重打浆,过滤,滤饼放置于65℃下烘干,得到灰白色固体产品36.7g,收率75.5%。HPLC显示纯度98.0%。LCMS[M+H]=371.1,NMR(DMSO-d6,400MHz):8.95(s,1H),8.24(d,1H),8.10(d,1H),7.78(t,1H),7.45(dd,1H),7.10(d,1H),4.62(m,1H),4.42(s,3H),3.84(m,1H),3.42-3.35(m,2H),3.01(m,1H)。
实施例20:(R)-3-(3-氟-4-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)苯基)-5-(羟甲基)噁唑烷-2-酮的制备
在装有搅拌和温度计的三口烧瓶中加入5-(2-氟-4-碘苯基)-2-(2-甲基-2H-四唑-5-基)吡啶(50.0g,1eq),(R)-5-(羟甲基)噁唑烷-2-酮(23.0g,1.5eq),环己二胺(1.5g,0.1eq),碘化亚铜(1.3g,0.05eq),碳酸钾(36.3g,2.0eq)及DMF(500mL),N2置换后,于100-110℃下搅拌反应16小时,HPLC显示反应完全。减压蒸馏除去大部分溶剂,残留物加入1000mL水,加热回流1-2小时,冷却至70℃,抽滤,滤饼用DMF(150mL)打浆2小时,过滤,滤饼用水(300mL)重打浆,过滤,滤饼放置于65℃下烘干,得到灰白色固体产品36.9g,收率76.0%。HPLC显示纯度99.5%。LCMS[M+H]=371.1,NMR(DMSO-d6,400MHz):8.95(s,1H),8.24(d,1H),8.10(d,1H),7.78(t,1H),7.45(dd,1H),7.10(d,1H),4.62(m,1H),4.42(s,3H),3.84(m,1H),3.42-3.35(m,2H),3.01(m,1H)。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明保护的范围之内。
Claims (18)
1.一种下式化合物的制备方法,
包括将具有下式结构的化合物
其中X为离去基团,所述离去基团选自氯、溴、碘,磺酰氧基,其中所述磺酰氧基为三氟甲磺酰氧基、甲磺酰氧基、或苯磺酰氧基,或被一个或多个取代基取代的苯磺酰氧基,所述取代基选自卤素、C1-C6烷基和C1-C6烷氧基组成的组,
与具有下式结构的化合物
在金属催化剂催化下进行偶联反应,R的定义同上,
其中所述金属催化剂为铜催化剂或钯催化剂,
其中当所述金属催化剂为铜催化剂时,所述铜催化剂与选自二胺类配体、二酮类配体、邻菲罗啉类配体、氨基酸类配体和Phos类配体的配体共同作用,
所述二胺类配体为:
所述二酮类配体为:
所述邻菲罗啉类配体为:
所述氨基酸类配体为:
所述Phos类配体为:X-Phos、XantPhos、RuPhos、BrettPhos、SPhos、DavePhos、JohnPhos、或tBuXPhos。
2.根据权利要求1所述的制备方法,其特征在于:铜催化剂选自CuI、CuBr、CuCl、CuO、Cu2O、CuSO4、Cu(OAc)2、Cu(OTf)2或Cu粉;钯催化剂选自氯化钯、醋酸钯、双(二亚苄基丙酮)钯、四(三苯基膦)钯、三(二亚苄基丙酮)二钯、[1,1’-双(二苯基磷)二茂铁]二氯化钯、双(三环己基膦)二氯化钯或双(三苯基膦)二氯化钯。
3.根据权利要求2所述的制备方法,其特征在于:所述铜催化剂为CuI或Cu(OAc)2,所述钯催化剂为三(二亚苄基丙酮)二钯、氯化钯或醋酸钯。
4.根据权利要求1-3中任一项所述的制备方法,其特征在于:所述偶联反应是在碱性物质作为促进剂作用下进行的。
5.根据权利要求4所述的制备方法,其特征在于:所述碱性物质选自碳酸钾、碳酸钠、碳酸铯、氟化铯、醋酸钾、氢氧化钠、氢氧化钾、磷酸钾或磷酸钠。
6.根据权利要求1-3中任一项所述的制备方法,其特征在于:所述偶联反应的反应溶剂为甲苯、氯苯、四氢呋喃、N,N-二甲基甲酰胺、二甲基亚砜、二氧六环、异丙醇、乙醇或乙腈;反应温度为60-110℃。
7.根据权利要求6所述的制备方法,其特征在于:所述偶联反应的反应溶剂为N,N-二甲基甲酰胺或二氧六环;反应温度为90-110℃。
8.一种下式化合物的制备方法,
其中X为离去基团,所述离去基团选自氯、溴、碘,磺酰氧基,其中所述磺酰氧基为三氟甲磺酰氧基、甲磺酰氧基、苯磺酰氧基,或被一个或多个取代基取代的苯磺酰氧基,所述取代基选自卤素、C1-C6烷基和C1-C6烷氧基组成的组;
包括将具有下式结构的化合物
其中,C为羟基或氨基;
1)当C为羟基时,与磺酰氯类化合物反应生成具有下式结构的化合物:
其中X为离去基团,所述离去基团为磺酰氧基,其中所述磺酰氧基为三氟甲磺酰氧基、甲磺酰氧基、苯磺酰氧基,或被一个或多个取代基取代的苯磺酰氧基,所述取代基选自卤素、C1-C6烷基和C1-C6烷氧基组成的组;或
2)当C为氨基时,在亚硝酸钠存在下反应生成重氮盐化合物,再经卤素离子取代形成具有下式结构的化合物:
其中X为离去基团,所述离去基团选自氯、溴、碘。
10.根据权利要求9所述的制备方法,其特征在于:所述离去基团的卤素为氯、溴、碘。
11.根据权利要求9所述的制备方法,其特征在于:B为离去基团,A为BF3或BR2R3,其中R2和R3独立的选自由OH和C1-C6一元和二元醇或卤素取代的C1-C6一元和二元醇组成的组,其中R2和R3可以成环;或
A为离去基团,B为BF3或BR2R3,其中R2和R3独立的选自由OH和C1-C6一元和二元醇或卤素取代的C1-C6一元和二元醇组成的组,其中R2和R3可以成环。
13.根据权利要求11所述的制备方法,其特征在于:所述离去基团为氯、溴、碘。
14.根据权利要求13所述的制备方法,其特征在于:所述离去基团为溴或碘。
15.根据权利要求9所述的制备方法,其特征在于:所述钯催化剂为氯化钯、醋酸钯、双(二亚苄基丙酮)钯、四(三苯基膦)钯、[1,1’-双(二苯基磷)二茂铁]二氯化钯、双(三环己基膦)二氯化钯或双(三苯基膦)二氯化钯。
16.根据权利要求9-11和15中任一项所述的制备方法,其特征在于:所述偶联反应的反应溶剂为水、甲苯、四氢呋喃、N,N-二甲基甲酰胺、二甲基亚砜、二氧六环、异丙醇、乙醇或乙腈中的一种或其任意组合;反应温度为50-120℃。
17.根据权利要求16所述的制备方法,其特征在于:所述偶联反应的反应溶剂为甲苯、水和二氧六环、或异丙醇;反应温度为70-100℃。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510739910.6A CN106632298B (zh) | 2015-11-03 | 2015-11-03 | 一种泰地唑胺的制备方法及其中间体 |
CN2015107399106 | 2015-11-03 | ||
PCT/CN2016/104311 WO2017076285A1 (zh) | 2015-11-03 | 2016-11-02 | 一种泰地唑胺的制备方法及其中间体和制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108368100A CN108368100A (zh) | 2018-08-03 |
CN108368100B true CN108368100B (zh) | 2021-07-23 |
Family
ID=58661614
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510739910.6A Active CN106632298B (zh) | 2015-11-03 | 2015-11-03 | 一种泰地唑胺的制备方法及其中间体 |
CN201680054697.8A Active CN108368100B (zh) | 2015-11-03 | 2016-11-02 | 一种泰地唑胺的制备方法及其中间体和制备方法 |
CN201680054647.XA Active CN108430999B (zh) | 2015-11-03 | 2016-11-02 | 一种噁唑烷酮中间体的制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510739910.6A Active CN106632298B (zh) | 2015-11-03 | 2015-11-03 | 一种泰地唑胺的制备方法及其中间体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680054647.XA Active CN108430999B (zh) | 2015-11-03 | 2016-11-02 | 一种噁唑烷酮中间体的制备方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US10590154B2 (zh) |
EP (2) | EP3372597A4 (zh) |
CN (3) | CN106632298B (zh) |
WO (2) | WO2017076293A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108383807B (zh) * | 2018-04-12 | 2020-10-27 | 深圳市前海博扬研究院有限公司 | 一种降低醚化反应含盐废水排放的方法 |
CN110938058B (zh) * | 2018-09-22 | 2022-04-12 | 南京优科生物医药研究有限公司 | 一种噁唑烷酮类抗生素中间体的制备方法 |
CN111116652A (zh) * | 2019-12-06 | 2020-05-08 | 山东中医药大学 | 一种高纯度磷酸特地唑胺的制备方法 |
CN111514935B (zh) * | 2020-04-30 | 2022-11-15 | 中国工程物理研究院化工材料研究所 | 一种面向含能离子液体-双氧水的自点火催化剂及其制备方法 |
CA3183397A1 (en) | 2020-06-18 | 2021-12-23 | Daryl C. Drummond | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof |
CN114105946A (zh) * | 2020-08-26 | 2022-03-01 | 浙江苏泊尔制药有限公司 | 一种磷酸特地唑胺中间体及其制备方法 |
CN113354620B (zh) | 2021-07-05 | 2022-03-22 | 南京桦冠生物技术有限公司 | 一种特地唑胺中间体的高效制备方法及其中间体 |
CN113620897A (zh) * | 2021-09-06 | 2021-11-09 | 南京杰运医药科技有限公司 | 一种噁唑烷酮类化合物的制备方法 |
CN115792047B (zh) * | 2023-02-10 | 2023-05-19 | 四川美域高生物医药科技有限公司 | 一种磷酸特地唑胺中间体有关物质的检测方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004056818A1 (en) * | 2002-12-19 | 2004-07-08 | Astrazeneca Ab | Oxazolidinone derivatives as antibacterial |
CN1894242A (zh) * | 2003-12-18 | 2007-01-10 | 东亚制药株式会社 | 新型噁唑烷酮衍生物 |
CN102177156A (zh) * | 2008-10-10 | 2011-09-07 | 特留斯治疗学公司 | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 |
CN104327119A (zh) * | 2014-10-17 | 2015-02-04 | 苏州明锐医药科技有限公司 | 磷酸泰地唑胺的制备方法 |
CN104496979A (zh) * | 2014-09-17 | 2015-04-08 | 博瑞生物医药技术(苏州)有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
CN104892592A (zh) * | 2015-03-30 | 2015-09-09 | 成都惟新医药科技有限公司 | 一种泰地唑胺的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403804B1 (en) * | 1998-12-07 | 2002-06-11 | Takasago International Corporation | Process for preparing optically active oxazolidinone derivative |
US7910747B2 (en) * | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
CN102850288A (zh) * | 2011-06-28 | 2013-01-02 | 袁建勇 | 一种利奈唑胺的制备方法 |
US8889671B2 (en) | 2013-01-23 | 2014-11-18 | Astrazeneca Ab | Compounds and methods for treating bacterial infections |
CN103304594B (zh) * | 2013-06-18 | 2015-07-08 | 上海科利生物医药有限公司 | 一种L-α-甘油磷酸胆碱的制备方法 |
-
2015
- 2015-11-03 CN CN201510739910.6A patent/CN106632298B/zh active Active
-
2016
- 2016-11-02 EP EP16861561.5A patent/EP3372597A4/en not_active Withdrawn
- 2016-11-02 US US15/771,449 patent/US10590154B2/en active Active
- 2016-11-02 EP EP16861553.2A patent/EP3372596B1/en active Active
- 2016-11-02 CN CN201680054697.8A patent/CN108368100B/zh active Active
- 2016-11-02 US US15/772,521 patent/US10385079B2/en active Active
- 2016-11-02 WO PCT/CN2016/104360 patent/WO2017076293A1/zh active Application Filing
- 2016-11-02 WO PCT/CN2016/104311 patent/WO2017076285A1/zh active Application Filing
- 2016-11-02 CN CN201680054647.XA patent/CN108430999B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004056818A1 (en) * | 2002-12-19 | 2004-07-08 | Astrazeneca Ab | Oxazolidinone derivatives as antibacterial |
CN1894242A (zh) * | 2003-12-18 | 2007-01-10 | 东亚制药株式会社 | 新型噁唑烷酮衍生物 |
CN102177156A (zh) * | 2008-10-10 | 2011-09-07 | 特留斯治疗学公司 | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 |
CN104496979A (zh) * | 2014-09-17 | 2015-04-08 | 博瑞生物医药技术(苏州)有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
CN104327119A (zh) * | 2014-10-17 | 2015-02-04 | 苏州明锐医药科技有限公司 | 磷酸泰地唑胺的制备方法 |
CN104892592A (zh) * | 2015-03-30 | 2015-09-09 | 成都惟新医药科技有限公司 | 一种泰地唑胺的制备方法 |
Non-Patent Citations (4)
Title |
---|
CuI/N,N-dimethylglycine-catalyzed synthesis of N-aryloxazolidinones from aryl bromides;Jiaojiao Li,等;《Tetrahedron Letters》;20120526;第53卷;第3981-3983页 * |
Highly Efficient CuI-Catalyzed Coupling of Aryl Bromides with Oxazolidinones Using Buchwald’s Protocol: A Short Route to Linezolid and Toloxatone;B. Mallesham,等;《Organic Letters》;20030304;第5卷(第7期);第963-965页 * |
Regioselective and Stereospecific Synthesis of Enantiopure 1,3-Oxazolidin-2-ones by Intramolecular Ring Opening of 2-(Boc-aminomethyl)aziridines. Preparation of the Antibiotic Linezolid;Roberto Mora´n-Ramalla,等;《Organic Letters》;20080424;第10卷(第10期);第1935-1938页 * |
RN:1638760-07-2;ACS;《STN Registry数据库》;20141215;第1页 * |
Also Published As
Publication number | Publication date |
---|---|
CN106632298A (zh) | 2017-05-10 |
CN106632298B (zh) | 2021-06-01 |
CN108430999B (zh) | 2021-07-23 |
EP3372596B1 (en) | 2020-07-22 |
CN108430999A (zh) | 2018-08-21 |
US20180312476A1 (en) | 2018-11-01 |
EP3372596A4 (en) | 2019-05-08 |
US20180319828A1 (en) | 2018-11-08 |
EP3372597A4 (en) | 2019-08-28 |
US10385079B2 (en) | 2019-08-20 |
CN108368100A (zh) | 2018-08-03 |
EP3372597A1 (en) | 2018-09-12 |
EP3372596A1 (en) | 2018-09-12 |
WO2017076293A1 (zh) | 2017-05-11 |
WO2017076285A1 (zh) | 2017-05-11 |
US10590154B2 (en) | 2020-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108368100B (zh) | 一种泰地唑胺的制备方法及其中间体和制备方法 | |
US10981909B2 (en) | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
EP2346858B1 (en) | Methods for preparing oxazolidinones and compositions containing them | |
CN108047261A (zh) | 一种克立硼罗的制备方法 | |
CN102821609B (zh) | 用于制备苯并氧杂硼杂环戊烯的方法 | |
WO2016041508A1 (zh) | 一种噁唑烷酮类化合物及其中间体的制备方法 | |
TW201602101A (zh) | 製造稠合雜環化合物之方法 | |
CN105777710B (zh) | 一种艾乐替尼的合成方法 | |
JP7347852B2 (ja) | 重水素化大環状化合物の調製方法 | |
CN103391927A (zh) | 利奈唑胺及其新中间体的新制备方法 | |
JP7405967B2 (ja) | テジゾリド中間体の効率的な調製方法及びその中間体 | |
CN110938058B (zh) | 一种噁唑烷酮类抗生素中间体的制备方法 | |
WO2010091272A1 (en) | Methods and processes for syntheses and manufacture of antimicrobial 1-(ortho-fluorophenyl)dihydropyridones | |
EP3365332A1 (en) | Preparation method of intermediate for oxazolidinone derivative | |
CN108707100B (zh) | 一种艾瑞昔布中间体以及艾瑞昔布的制备方法 | |
TW201504215A (zh) | 嗒□化合物之製造方法 | |
WO2008032702A1 (fr) | Composé de fluorobore ayant un noyau aromatique ou sel de celui-ci, et procédé de fabrication du composé ayant un noyau aromatique fusionné à un éther cyclique à l'aide de celui-ci | |
JP4568824B2 (ja) | ジアリールスルホン酸誘導体の製造方法 | |
CN111909040A (zh) | 一种Elagolix中间体2-氟-6-三氟甲基苄胺的制备方法 | |
CN115772176A (zh) | 左氧氟沙星关键药物中间体的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |